drugset / Trial / NCT05063565
TheraSphere With Durvalumab and Tremelimumab for HCC
Phase 2
Active not recruiting
100 enrolled
Boston Scientific Corporation
Biocompatibles UK Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.
Timeline
- Start
- 2023-11-03
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Tremelimumab | Monoclonal antibody | 300 mg | — |